Clinical trial
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT02547428 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Development & Commercialization, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 3, 2015
- Completion date
- June 4, 2016
- Enrollment
- 85 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.